U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
11,240.00+100.00 (+0.90%)
At close: 5:24PM IDT
Full screen
Previous Close11,140.00
Bid11,230.00 x 200
Ask11,240.00 x 34100
Day's Range10,950.00 - 11,250.00
52 Week Range99.40 - 11,250.00
Avg. Volume466,019
Market Cap114.2B
PE Ratio (TTM)144,102.56
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Forbes11 hours ago

    Facebook, Baidu, Coach And 5 Other Blue-Chip Stocks To Buy For Second-Half 2017

    The bull market that kicked off in March 2009 should be on the front cover of AARP magazine. At age 8, the S&P 500 bull run is very old and very overvalued compared to its historical ratios. Given the less than stellar circumstances, how should you invest now?

  • Glaxo's (GSK) Shingles Candidate Phase III Data Positive
    Zacks2 days ago

    Glaxo's (GSK) Shingles Candidate Phase III Data Positive

    GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

  • Reuters3 days ago

    GSK wins $235 million from Teva in Coreg patent trial

    A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A federal jury in Wilmington, Delaware on Tuesday found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The jury rejected Teva's contention that the patent was invalid.